Correction to Lancet Gastroenterol Hepatol 2022; 7: 294–306 (The Lancet Gastroenterology & Hepatology (2022) 7(4) (294–306), (S246812532100474X), (10.1016/S2468-1253(21)00474-X))

Silvio Danese; Severine Vermeire; Geert D'Haens; Julian Panés; Axel Dignass; Fernando Magro; Maciej Nazar; Manuela Le Bars; Marjolein Lahaye; Lioudmila Ni; Ivana Bravata; Frederic Lavie; Marco Daperno; Milan Lukáš; Alessandro Armuzzi; Mark Löwenberg; Daniel R. Gaya; Laurent Peyrin-Biroulet; STARDUST study group; Craig Mowat

doi:10.1016/S2468-1253(22)00055-3

Correction to Lancet Gastroenterol Hepatol 2022; 7: 294–306 (The Lancet Gastroenterology & Hepatology (2022) 7(4) (294–306), (S246812532100474X), (10.1016/S2468-1253(21)00474-X))

Silvio Danese (Lead / Corresponding author)
, Severine Vermeire
, Geert D'Haens
, Julian Panés
, Axel Dignass
, Fernando Magro
, Maciej Nazar
, Manuela Le Bars
, Marjolein Lahaye
, Lioudmila Ni
, Ivana Bravata
, Frederic Lavie
, Marco Daperno
, Milan Lukáš
, Alessandro Armuzzi
, Mark Löwenberg
, Daniel R. Gaya
, Laurent Peyrin-Biroulet
, STARDUST study group
, Craig Mowat (Contributing member)

Population Health and Genomics

Research output: Contribution to journal › Article › peer-review

Abstract

Danese S, Vermeire S, D'Haens G, et al. Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol 2022; 7: 294–306—In this Article, the author byline should end “on behalf of the STARDUST study group”. Members of the study group are shown in the appendix. This correction has been made as of March 9, 2022.

Original language	English
Pages (from-to)	e8
Journal	The Lancet Gastroenterology and Hepatology
Volume	7
Issue number	4
DOIs	https://doi.org/10.1016/S2468-1253(22)00055-3
Publication status	Published - 1 Feb 2022

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1016/S2468-1253(22)00055-3Licence: Elsevier User Licence

Cite this

Danese, S., Vermeire, S., D'Haens, G., Panés, J., Dignass, A., Magro, F., Nazar, M., Le Bars, M., Lahaye, M., Ni, L., Bravata, I., Lavie, F., Daperno, M., Lukáš, M., Armuzzi, A., Löwenberg, M., Gaya, D. R., Peyrin-Biroulet, L., STARDUST study group, & Mowat, C. (2022). Correction to Lancet Gastroenterol Hepatol 2022; 7: 294–306 (The Lancet Gastroenterology & Hepatology (2022) 7(4) (294–306), (S246812532100474X), (10.1016/S2468-1253(21)00474-X)). The Lancet Gastroenterology and Hepatology, 7(4), e8. https://doi.org/10.1016/S2468-1253(22)00055-3

@article{695723f5bded4c40be5034cc6251c6a9,

title = "Correction to Lancet Gastroenterol Hepatol 2022; 7: 294–306 (The Lancet Gastroenterology \& Hepatology (2022) 7(4) (294–306), (S246812532100474X), (10.1016/S2468-1253(21)00474-X))",

abstract = "Danese S, Vermeire S, D'Haens G, et al. Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol 2022; 7: 294–306—In this Article, the author byline should end “on behalf of the STARDUST study group”. Members of the study group are shown in the appendix. This correction has been made as of March 9, 2022.",

author = "Silvio Danese and Severine Vermeire and Geert D'Haens and Julian Pan{\'e}s and Axel Dignass and Fernando Magro and Maciej Nazar and \{Le Bars\}, Manuela and Marjolein Lahaye and Lioudmila Ni and Ivana Bravata and Frederic Lavie and Marco Daperno and Milan Luk{\'a}{\v s} and Alessandro Armuzzi and Mark L{\"o}wenberg and Gaya, \{Daniel R.\} and Laurent Peyrin-Biroulet and \{STARDUST study group\} and Rodolfo Rocca and Susana Lopes and Flavio Caprioli and Sandro Ardizzone and \{Echarri Piudo\}, Ana and Paolo Gionchetti and Xavier Roblin and Ursula Seidler and David Andersson and Kamal Patel and Pierre Desreumaux and Simone Saibeni and Gustav From and Miroslav Fedurco and Milos Gregus and Yoram Bouhnik and Andreas Luegering and Rocco Cosintino and Ivan Bunganic and Jaime Ramos and \{Aguas Peris\}, Mariam and Olivier Dewit and Mariabeatrice Principi and Emma Wesley and Paula Lago and Stephane Nancey and \{Mart{\'i}n Arranz\}, \{Mar{\'i}a Dolores\} and Pieter Hindryckx and Ambrogio Orlando and Andrea Geccherle and Annunziata, \{Maria Laura\} and Craig Mowat",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = feb,

day = "1",

doi = "10.1016/S2468-1253(22)00055-3",

language = "English",

volume = "7",

pages = "e8",

journal = "The Lancet Gastroenterology and Hepatology",

issn = "2468-1253",

publisher = "Elsevier",

number = "4",

}

Danese, S, Vermeire, S, D'Haens, G, Panés, J, Dignass, A, Magro, F, Nazar, M, Le Bars, M, Lahaye, M, Ni, L, Bravata, I, Lavie, F, Daperno, M, Lukáš, M, Armuzzi, A, Löwenberg, M, Gaya, DR, Peyrin-Biroulet, L, STARDUST study group & Mowat, C 2022, 'Correction to Lancet Gastroenterol Hepatol 2022; 7: 294–306 (The Lancet Gastroenterology & Hepatology (2022) 7(4) (294–306), (S246812532100474X), (10.1016/S2468-1253(21)00474-X))', The Lancet Gastroenterology and Hepatology, vol. 7, no. 4, pp. e8. https://doi.org/10.1016/S2468-1253(22)00055-3

Correction to Lancet Gastroenterol Hepatol 2022; 7: 294–306 (The Lancet Gastroenterology & Hepatology (2022) 7(4) (294–306), (S246812532100474X), (10.1016/S2468-1253(21)00474-X)). / Danese, Silvio (Lead / Corresponding author); Vermeire, Severine; D'Haens, Geert et al.
In: The Lancet Gastroenterology and Hepatology, Vol. 7, No. 4, 01.02.2022, p. e8.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Correction to Lancet Gastroenterol Hepatol 2022; 7

T2 - 294–306 (The Lancet Gastroenterology & Hepatology (2022) 7(4) (294–306), (S246812532100474X), (10.1016/S2468-1253(21)00474-X))

AU - Danese, Silvio

AU - Vermeire, Severine

AU - D'Haens, Geert

AU - Panés, Julian

AU - Dignass, Axel

AU - Magro, Fernando

AU - Nazar, Maciej

AU - Le Bars, Manuela

AU - Lahaye, Marjolein

AU - Ni, Lioudmila

AU - Bravata, Ivana

AU - Lavie, Frederic

AU - Daperno, Marco

AU - Lukáš, Milan

AU - Armuzzi, Alessandro

AU - Löwenberg, Mark

AU - Gaya, Daniel R.

AU - Peyrin-Biroulet, Laurent

AU - STARDUST study group

AU - Rocca, Rodolfo

AU - Lopes, Susana

AU - Caprioli, Flavio

AU - Ardizzone, Sandro

AU - Echarri Piudo, Ana

AU - Gionchetti, Paolo

AU - Roblin, Xavier

AU - Seidler, Ursula

AU - Andersson, David

AU - Patel, Kamal

AU - Desreumaux, Pierre

AU - Saibeni, Simone

AU - From, Gustav

AU - Fedurco, Miroslav

AU - Gregus, Milos

AU - Bouhnik, Yoram

AU - Luegering, Andreas

AU - Cosintino, Rocco

AU - Bunganic, Ivan

AU - Ramos, Jaime

AU - Aguas Peris, Mariam

AU - Dewit, Olivier

AU - Principi, Mariabeatrice

AU - Wesley, Emma

AU - Lago, Paula

AU - Nancey, Stephane

AU - Martín Arranz, María Dolores

AU - Hindryckx, Pieter

AU - Orlando, Ambrogio

AU - Geccherle, Andrea

AU - Annunziata, Maria Laura

A2 - Mowat, Craig

PY - 2022/2/1

Y1 - 2022/2/1

N2 - Danese S, Vermeire S, D'Haens G, et al. Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol 2022; 7: 294–306—In this Article, the author byline should end “on behalf of the STARDUST study group”. Members of the study group are shown in the appendix. This correction has been made as of March 9, 2022.

AB - Danese S, Vermeire S, D'Haens G, et al. Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol 2022; 7: 294–306—In this Article, the author byline should end “on behalf of the STARDUST study group”. Members of the study group are shown in the appendix. This correction has been made as of March 9, 2022.

UR - https://www.scopus.com/pages/publications/85125879717

U2 - 10.1016/S2468-1253(22)00055-3

DO - 10.1016/S2468-1253(22)00055-3

M3 - Article

C2 - 35278403

SN - 2468-1253

VL - 7

SP - e8

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

IS - 4

ER -

Correction to Lancet Gastroenterol Hepatol 2022; 7: 294–306 (The Lancet Gastroenterology & Hepatology (2022) 7(4) (294–306), (S246812532100474X), (10.1016/S2468-1253(21)00474-X))

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

Cite this